Tuberculosis (TB) remains a major cause of mortality and morbidity worldwide. Currently, a third of the world's population is infected with Mycobacterium tuberculosis, the causative agent of TB, and annually there are 10 million new cases of clinical TB and approximately 2 million deaths [1] . TB kills more individuals each year than any other bacterial pathogen, and alarmingly, current control practices have not been able to significantly reduce the incidence of the disease over the past 15 years [1] . The current vaccine in use, Mycobacterium bovis bacille Calmette-Guérin (BCG), has been unable to limit the transmission of the disease, and the problem is compounded by the HIV/AIDS pandemic and the emergence of multidrug resistant strains of M. tuberculosis including extensively drug-resistant strains in multiple countries [2] . There is thus an urgent need to better understand the host response to M. tuberculosis and develop more effective strategies to control TB.
This special issue contains original research reports and review articles covering a number of aspects of TB immunity. The first series of articles focuses on immune response to M. tuberculosis in humans. These studies range from the expression of cytolytic mediators following BCG vaccination in children (P. In conclusion, the aspects of immunity to M. tuberculosis infection, host-pathogen interaction and vaccine development covered in this special issue may lead to future advances in the treatment and control of TB.
